http://www.marketwatch.com/story/whittemore-peterson-institute-and-cerus-confirm-inactivation-of-xmrv-by-the-intercept-blood-system-2010-05-18?reflink=MW_news_stmp
CONCORD, Calif. & RENO, Nev., May 18, 2010 (BUSINESS WIRE) -- The Whittemore Peterson Institute for Neuro-Immune Disease (WPI) and Cerus Corporation /quotes/comstock/15*!cers/quotes/nls/cers (CERS 2.90, +0.04, +1.40%) announced positive results from a study demonstrating the efficacy of the INTERCEPT Blood System to inactivate XMRV, a human retrovirus, in donated platelet components. After sample platelet components were inoculated with XMRV, the infected blood components were treated with INTERCEPT, a system that inactivates pathogens in donated blood. Following treatment, no evidence of infectious XMRV was detected in blood samples. The study results have been submitted for presentation at the AABB Annual Meeting in October.
CONCORD, Calif. & RENO, Nev., May 18, 2010 (BUSINESS WIRE) -- The Whittemore Peterson Institute for Neuro-Immune Disease (WPI) and Cerus Corporation /quotes/comstock/15*!cers/quotes/nls/cers (CERS 2.90, +0.04, +1.40%) announced positive results from a study demonstrating the efficacy of the INTERCEPT Blood System to inactivate XMRV, a human retrovirus, in donated platelet components. After sample platelet components were inoculated with XMRV, the infected blood components were treated with INTERCEPT, a system that inactivates pathogens in donated blood. Following treatment, no evidence of infectious XMRV was detected in blood samples. The study results have been submitted for presentation at the AABB Annual Meeting in October.